title: Identification of muscarinic receptor subtypes present in cerebellar granule cells: prevention of [3H]propylbenzilyl choline mustard binding with specific antagonists.
abstract: Subtypes of muscarinic receptors (possible m1 to m5) can be identified by their molecular size, specific effector systems and antagonist specificity. In membranes prepared from primary cultures of cerebellar granule cells, [3H]propylbenzilylcholine mustard [( 3H]PBCM) irreversibly binds to muscarinic receptive proteins, having two major molecular sizes, 92 and 66 kDa. With relatively short periods of incubation (approx. 30 min, 30 degrees C) of [3H]PBCM with atropine, a nonspecific competitive receptor antagonist, the irreversible labeling of these muscarinic proteins by [3H]PBCM could be prevented. Methoctramine, a specific competitive antagonist at muscarinic receptors coupled to inhibition of adenylate cyclase, protected most of the muscarinic receptors having a molecular size of 66 kDa from binding of [3H]PBCM. These 66 kDa receptive proteins are suggested to be muscarinic m2 and m4 subtypes. (-)Quinuclidinyl xanthene-9-carboxylate [(-)QNX], a somewhat specific competitive antagonist at muscarinic receptors coupled to hydrolysis of phosphatidylinositol, prevented the binding of [3H]PBCM to 92 kDa muscarinic receptive proteins and some 66 kDa muscarinic receptive proteins. The 92 kDa receptive proteins are suggested to be the muscarinic m3 subtype and the 66 kDa proteins could be either the m2 or m4 receptor subtype. Lastly, pirenzepine, a nonspecific antagonist at muscarinic receptors mediating inhibition of adenylate cyclase and hydrolysis of PI in these cultures, resembled (-)QNX in preventing binding of [3H]PBCM to the 92 kDa receptive proteins and some 66 kDa receptive proteins. The suggested subtypes of muscarinic receptors, specifically bound by pirenzepine should be the m3 (92 kDa) and the m4 (66 kDa) subtypes, since pirenzepine reportedly exhibits a low affinity for the muscarinic m2 subtype.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Fidia Georgetown Institute for the Neurosciences, Georgetown University, School of Medicine, Washington D.C. 20007.
authors.forename: S W
authors.initials: SW
authors.lastname: McLeskey
authors.forename: W J
authors.initials: WJ
authors.lastname: Wojcik
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology / Q000378:metabolism*; D003959:Diamines / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D010276:Parasympatholytics / Q000494:pharmacology*; D010890:Pirenzepine / Q000494:pharmacology; D011438:Propylbenzilylcholine Mustard / Q000378:metabolism*; D011812:Quinuclidines; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D014966:Xanthenes
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D003959:Diamines; D010276:Parasympatholytics; D011812:Quinuclidines; D011976:Receptors, Muscarinic; D014966:Xanthenes; C067669:3-quinuclidinyl xanthene-9-carboxylate; D011438:Propylbenzilylcholine Mustard; D010890:Pirenzepine; D001285:Atropine; C054938:methoctramine